The purpose of this study is to investigate the efficacy of a treatment with TMC435 in
combination with peginterferon alfa-2a and ribavirin in patients who did not clear their
hepatitis C infection with peginterferon alfa-2a and ribavirin alone within a previous trial
conducted by Tibotec, or who participated in Tibotec trials in which antivirals directed
against hepatitis C virus (HCV) were evaluated for short periods of time.